We provide you with 20 years of free, institutional-grade data for SIOX stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of SIOX. Explore the full financial landscape of SIOX stock.
| Reported Date | CIK | Ticker | Type |
|---|
Sio Gene Therapies, Inc(NASDAQ:SIOX) 
Sio Gene Therapies, Inc., a clinical-stage gene therapy company, focuses on developing various product candidates for debilitating neurodegenerative diseases. The company's clinical-stage programs include AXO-Lenti-PD program for the treatment of Parkinson's disease; AXO-AAV-GM1 program for the trea...
Website: http://www.axovant.com/
Founded: 2014
Full Time Employees: 38
CEO: Pavan Cheruvu
Sector: Healthcare
Industry: Biotechnology
Share this website to your friends
The information provided in this report about SIOX stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.